Madrigal Pharmaceuticals Stock Price, News & Analysis (NASDAQ:MDGL)

$111.67 7.04 (6.73 %)
(As of 01/19/2018 06:22 AM ET)
Previous Close$104.63
Today's Range$104.01 - $113.25
52-Week Range$13.09 - $113.25
Volume230,900 shs
Average Volume138,483 shs
Market Capitalization$1.47 billion
P/E Ratio-43.96
Dividend YieldN/A
Beta0.8

About Madrigal Pharmaceuticals (NASDAQ:MDGL)

Madrigal Pharmaceuticals logoMadrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Receive MDGL News and Ratings via Email

Sign-up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MDGL
CUSIP87162T20
Phone484-380-9263

Debt

Debt-to-Equity RatioN/A
Current Ratio7.36%
Quick Ratio7.36%

Price-To-Earnings

Trailing P/E Ratio-43.9645669291339
Forward P/E Ratio-43.45
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.15 per share
Price / Book35.45

Profitability

Trailing EPS($2.54)
Net Income$-26,380,000.00
Net MarginsN/A
Return on Equity-65.22%
Return on Assets-57.35%

Miscellaneous

Employees8
Outstanding Shares14,000,000

Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions

What is Madrigal Pharmaceuticals' stock symbol?

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) posted its quarterly earnings results on Thursday, November, 9th. The biopharmaceutical company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.11. View Madrigal Pharmaceuticals' Earnings History.

Where is Madrigal Pharmaceuticals' stock going? Where will Madrigal Pharmaceuticals' stock price be in 2018?

4 Wall Street analysts have issued 1-year target prices for Madrigal Pharmaceuticals' stock. Their forecasts range from $105.00 to $170.00. On average, they anticipate Madrigal Pharmaceuticals' stock price to reach $135.00 in the next twelve months. View Analyst Ratings for Madrigal Pharmaceuticals.

Who are some of Madrigal Pharmaceuticals' key competitors?

Who are Madrigal Pharmaceuticals' key executives?

Madrigal Pharmaceuticals' management team includes the folowing people:

  • Paul A. Friedman M.D., Chairman of the Board, Chief Executive Officer (Age 74)
  • Rebecca A. Taub M.D., Founder, Chief Medical Officer, Executive Vice President, Research & Development and Director (Age 65)
  • Marc R. Schneebaum, Chief Financial Officer, Senior Vice President (Age 63)
  • Frederick B. Craves Ph.D., Lead Independent Director (Age 70)
  • Kenneth M. Bate, Independent Director (Age 66)
  • Keith R. Gollust, Independent Director (Age 71)
  • Richard S. Levy M.D., Independent Director (Age 59)
  • David V. Milligan Ph.D., Independent Director (Age 76)

Who owns Madrigal Pharmaceuticals stock?

Madrigal Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.06%). View Institutional Ownership Trends for Madrigal Pharmaceuticals.

Who sold Madrigal Pharmaceuticals stock? Who is selling Madrigal Pharmaceuticals stock?

Madrigal Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Madrigal Pharmaceuticals.

How do I buy Madrigal Pharmaceuticals stock?

Shares of Madrigal Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Madrigal Pharmaceuticals' stock price today?

One share of Madrigal Pharmaceuticals stock can currently be purchased for approximately $111.67.

How big of a company is Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals has a market capitalization of $1.47 billion. The biopharmaceutical company earns $-26,380,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. Madrigal Pharmaceuticals employs 8 workers across the globe.

How can I contact Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at 484-380-9263 or via email at [email protected]


MarketBeat Community Rating for Madrigal Pharmaceuticals (MDGL)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  275
MarketBeat's community ratings are surveys of what our community members think about Madrigal Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Madrigal Pharmaceuticals (NASDAQ:MDGL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $135.00$135.00$63.33$40.00
Price Target Upside: 65.50% upside65.50% upside33.28% upside168.46% upside

Madrigal Pharmaceuticals (NASDAQ:MDGL) Consensus Price Target History

Price Target History for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Madrigal Pharmaceuticals (NASDAQ:MDGL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/11/2017Roth CapitalBoost Price TargetBuy$82.00 -> $170.00LowView Rating Details
12/7/2017Evercore ISIBoost Price TargetOutperform$65.00 -> $140.00LowView Rating Details
12/6/2017JMP SecuritiesBoost Price TargetOutperform$63.00 -> $125.00HighView Rating Details
12/6/2017HC WainwrightBoost Price TargetBuy -> Buy$54.00 -> $105.00HighView Rating Details
(Data available from 1/19/2016 forward)

Earnings

Madrigal Pharmaceuticals (NASDAQ:MDGL) Earnings History and Estimates Chart

Earnings by Quarter for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Madrigal Pharmaceuticals (NASDAQ MDGL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.79)($0.68)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.60)($0.69)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.87)($0.50)ViewN/AView Earnings Details
4/3/2017Q4 2016($1.39)($0.67)ViewN/AView Earnings Details
11/14/2016Q3 2016($1.34)ViewN/AView Earnings Details
7/20/2016Q2 2016($0.70)ViewN/AView Earnings Details
5/10/2016Q1 2016($1.75)ViewN/AView Earnings Details
3/15/2016Q4($0.18)($0.08)ViewN/AView Earnings Details
11/5/2015Q3($0.16)($0.13)ViewN/AView Earnings Details
8/6/2015Q215($0.18)($0.15)ViewListenView Earnings Details
5/7/2015Q115($0.19)($0.19)ViewListenView Earnings Details
3/12/2015Q4($0.19)($0.19)$0.13 millionViewListenView Earnings Details
11/6/2014Q3($0.23)($0.19)$0.13 millionViewListenView Earnings Details
8/6/2014Q2($0.25)($0.24)$480.00 millionViewListenView Earnings Details
5/8/2014Q1($0.28)($0.28)ViewListenView Earnings Details
3/11/2014Q4($0.30)($0.31)$0.37 millionViewListenView Earnings Details
11/4/2013Q313($0.31)($0.33)ViewListenView Earnings Details
8/1/2013Q2 2013($0.30)($0.33)ViewListenView Earnings Details
4/30/2013Q1 2013($9.79)($10.49)ViewN/AView Earnings Details
3/14/2013Q4 2012($9.44)($10.14)ViewN/AView Earnings Details
11/6/2012Q312($0.24)($0.25)$1.60 millionViewN/AView Earnings Details
8/2/2012Q2 2012($9.44)($8.88)ViewN/AView Earnings Details
5/3/2012Q1 2012($8.74)($9.44)ViewN/AView Earnings Details
2/22/2012Q4 2011($9.44)($7.59)ViewN/AView Earnings Details
11/3/2011Q3 2011($9.79)($10.56)ViewN/AView Earnings Details
8/4/2011Q2 2011($6.64)($10.35)ViewN/AView Earnings Details
5/5/2011Q1 2011($9.44)($9.48)ViewN/AView Earnings Details
3/11/2011Q4 2010($5.24)($7.48)ViewN/AView Earnings Details
11/4/2010Q3 2010($7.69)($8.88)ViewN/AView Earnings Details
8/9/2010Q2 2010($8.04)($7.69)ViewN/AView Earnings Details
5/4/2010Q1 2010($7.34)($8.39)ViewN/AView Earnings Details
3/11/2010Q4 2009($9.09)($7.24)ViewN/AView Earnings Details
11/4/2009Q3 2009$61.19$121.82ViewN/AView Earnings Details
8/4/2009Q2 2009($11.89)($8.78)ViewN/AView Earnings Details
5/7/2009Q1 2009($18.88)($23.01)ViewN/AView Earnings Details
3/26/2009Q4 2008($28.32)($26.89)ViewN/AView Earnings Details
11/13/2008Q3 2008($22.38)($27.27)ViewN/AView Earnings Details
8/7/2008Q2 2008($19.93)($23.53)ViewN/AView Earnings Details
5/14/2008Q1 2008($19.23)($18.29)ViewN/AView Earnings Details
3/20/2008Q4 2007($18.18)($16.12)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Madrigal Pharmaceuticals (NASDAQ:MDGL) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.57 EPS
Next Year EPS Consensus Estimate: $-3.01 EPS

Dividends

Dividend History for Madrigal Pharmaceuticals (NASDAQ:MDGL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Madrigal Pharmaceuticals (NASDAQ MDGL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 66.40%
Institutional Ownership Percentage: 19.10%
Insider Trades by Quarter for Madrigal Pharmaceuticals (NASDAQ:MDGL)
Insider Trades by Quarter for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Madrigal Pharmaceuticals (NASDAQ MDGL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/23/2017Richard S LevyDirectorBuy2,000$16.12$32,240.007,200View SEC Filing  
8/22/2017Richard S LevyDirectorBuy3,550$16.12$57,226.003,640View SEC Filing  
8/21/2017Richard S LevyDirectorBuy3,550$15.88$56,374.00900View SEC Filing  
12/14/2015Keith R GollustDirectorSell600,000$0.35$210,000.00401,764View SEC Filing  
12/9/2015Keith R GollustDirectorSell745,892$0.38$283,438.96401,764View SEC Filing  
12/8/2015Bruce KovnerDirectorSell1,523,346$0.37$563,638.023,092,677View SEC Filing  
12/3/2015Bruce KovnerDirectorSell1,430,753$0.43$615,223.793,092,677View SEC Filing  
11/30/2015Bruce KovnerDirectorSell3,078,820$0.48$1,477,833.603,092,677View SEC Filing  
11/24/2015Bruce KovnerDirectorSell1,173,582$0.44$516,376.083,092,677View SEC Filing  
11/20/2015Bruce KovnerDirectorSell1,513,088$0.49$741,413.123,092,677View SEC Filing  
11/17/2015Bruce KovnerDirectorSell1,223,936$0.43$526,292.483,092,677View SEC Filing  
11/12/2015Bruce KovnerDirectorSell5,436,673$0.55$2,990,170.153,092,677View SEC Filing  
11/10/2015Keith R GollustDirectorSell188,322$0.55$103,577.10401,764View SEC Filing  
4/6/2015Robert N WilsonDirectorBuy50,000$1.75$87,500.00View SEC Filing  
9/30/2014Bruce KovnerDirectorBuy300,000$3.08$924,000.00View SEC Filing  
4/11/2014Bruce KovnerDirectorBuy1,250,000$4.01$5,012,500.003,048,666View SEC Filing  
11/13/2013Bruce KovnerDirectorBuy5,000,000$3.75$18,750,000.006,130,330View SEC Filing  
11/13/2013Safi BahcallCEOBuy20,000$3.75$75,000.002,053,135View SEC Filing  
6/28/2013Safi R BahcallCEOBuy10,000$5.03$50,300.00View SEC Filing  
6/27/2013Bruce KovnerDirectorBuy150,000$4.71$706,500.00View SEC Filing  
6/26/2013Bruce KovnerDirectorBuy500,000$4.53$2,265,000.00View SEC Filing  
6/21/2013Bruce KovnerDirectorBuy250,000$4.39$1,097,500.00View SEC Filing  
6/21/2013Safi R BahcallCEOBuy20,000$4.12$82,400.00View SEC Filing  
6/18/2013Bruce KovnerDirectorBuy200,000$4.00$800,000.00View SEC Filing  
6/14/2013Safi R BahcallCEOBuy10,000$4.06$40,600.00View SEC Filing  
6/6/2013Bruce KovnerDirectorBuy2,000,000$4.64$9,280,000.00View SEC Filing  
6/6/2013Safi R BahcallCEOBuy10,000$4.04$40,400.00View SEC Filing  
6/5/2013Vojo VukovicSVPBuy10,000$4.58$45,800.00View SEC Filing  
6/4/2013Robert N WilsonDirectorBuy10,000$5.00$50,000.00View SEC Filing  
11/14/2012Bruce KovnerDirectorBuy37,700$6.91$260,507.00View SEC Filing  
11/12/2012Safi R BahcallCEOBuy10,000$7.12$71,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Madrigal Pharmaceuticals (NASDAQ MDGL) News Headlines

Source:
DateHeadline
Madrigal Pharmaceuticals Inc (MDGL) Given Average Recommendation of "Buy" by BrokeragesMadrigal Pharmaceuticals Inc (MDGL) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 14 at 1:32 AM
Madrigal Pharmaceuticals (MDGL) Rating Lowered to Hold at Zacks Investment ResearchMadrigal Pharmaceuticals (MDGL) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 9 at 6:08 AM
5 Top Multibagger Stocks to Buy in 2018 - Nasdaq5 Top Multibagger Stocks to Buy in 2018 - Nasdaq
www.nasdaq.com - January 2 at 11:15 PM
5 Top Multibagger Stocks to Buy in 20185 Top Multibagger Stocks to Buy in 2018
finance.yahoo.com - January 2 at 9:42 AM
Madrigal Pharmaceuticals (MDGL) Upgraded at Zacks Investment ResearchMadrigal Pharmaceuticals (MDGL) Upgraded at Zacks Investment Research
www.americanbankingnews.com - December 24 at 12:26 AM
Madrigal Pharmaceuticals: Elucidating The Upcoming Binary Event ... - Seeking AlphaMadrigal Pharmaceuticals: Elucidating The Upcoming Binary Event ... - Seeking Alpha
seekingalpha.com - December 21 at 9:48 AM
Madrigal Pharmaceuticals: Buy The Secondary - Seeking Alpha - Seeking AlphaMadrigal Pharmaceuticals: Buy The Secondary - Seeking Alpha - Seeking Alpha
seekingalpha.com - December 21 at 9:48 AM
Montco biopharm seeking to raise $125MMontco biopharm seeking to raise $125M
www.bizjournals.com - December 20 at 5:03 PM
Madrigal Pharmaceuticals Inc (MDGL) Receives Average Recommendation of "Buy" from AnalystsMadrigal Pharmaceuticals Inc (MDGL) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 20 at 3:22 AM
Madrigal Pharmaceuticals Prices Public Offering of Common StockMadrigal Pharmaceuticals Prices Public Offering of Common Stock
finance.yahoo.com - December 19 at 9:49 AM
Madrigal Pharmaceuticals Announces Proposed Public Offering of Common StockMadrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock
finance.yahoo.com - December 18 at 10:05 AM
Madrigal Pharmaceuticals (MDGL) Price Target Raised to $170.00 at Roth CapitalMadrigal Pharmaceuticals (MDGL) Price Target Raised to $170.00 at Roth Capital
www.americanbankingnews.com - December 11 at 5:46 PM
Madrigal Pharmaceuticals, Inc. (MDGL) Expected to Announce Earnings of -$0.69 Per ShareMadrigal Pharmaceuticals, Inc. (MDGL) Expected to Announce Earnings of -$0.69 Per Share
www.americanbankingnews.com - December 9 at 8:04 AM
Madrigal Pharmaceuticals (MDGL) Price Target Raised to $140.00Madrigal Pharmaceuticals (MDGL) Price Target Raised to $140.00
www.americanbankingnews.com - December 7 at 5:40 PM
Multi-Billion Dollar Global Medical Device Industry Led by Cardiovascular Monitoring DevicesMulti-Billion Dollar Global Medical Device Industry Led by Cardiovascular Monitoring Devices
www.prnewswire.com - December 7 at 10:01 AM
Today’s Research Reports on Stocks to Watch: Madrigal Pharmaceuticals and VistaGen TherapeuticsToday’s Research Reports on Stocks to Watch: Madrigal Pharmaceuticals and VistaGen Therapeutics
finance.yahoo.com - December 7 at 10:01 AM
Heres Why Biotricity (BTCY) Could Make A Similar Move to Madrigal (MDGL) and Digital Power Corp (DPW)Here's Why Biotricity (BTCY) Could Make A Similar Move to Madrigal (MDGL) and Digital Power Corp (DPW)
finance.yahoo.com - December 7 at 10:01 AM
Mid-Afternoon Market Update: Vera Bradley Rises On Earnings Beat; Freds Shares Plunge - NasdaqMid-Afternoon Market Update: Vera Bradley Rises On Earnings Beat; Fred's Shares Plunge - Nasdaq
www.nasdaq.com - December 6 at 5:08 PM
Why Madrigal Pharmaceuticals Stock Is On Fire TodayWhy Madrigal Pharmaceuticals Stock Is On Fire Today
finance.yahoo.com - December 6 at 5:08 PM
Why Brown-Forman, H&R Block, and Madrigal Pharmaceuticals Jumped TodayWhy Brown-Forman, H&R Block, and Madrigal Pharmaceuticals Jumped Today
finance.yahoo.com - December 6 at 5:08 PM
Madrigal Pharmaceuticals (MDGL) PT Raised to $125.00Madrigal Pharmaceuticals (MDGL) PT Raised to $125.00
www.americanbankingnews.com - December 6 at 4:22 PM
Madrigal Pharmaceuticals (MDGL) Given New $105.00 Price Target at HC WainwrightMadrigal Pharmaceuticals (MDGL) Given New $105.00 Price Target at HC Wainwright
www.americanbankingnews.com - December 6 at 12:40 PM
Madrigal Pharmaceuticals Inc. (MDGL) Has Surged To A New High On Study Results - NasdaqMadrigal Pharmaceuticals Inc. (MDGL) Has Surged To A New High On Study Results - Nasdaq
www.nasdaq.com - December 6 at 9:56 AM
Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Biopsy-proven Non-alcoholic Steatohepatitis (NASH) in Phase 2 Clinical TrialMadrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Biopsy-proven Non-alcoholic Steatohepatitis (NASH) in Phase 2 Clinical Trial
finance.yahoo.com - December 6 at 9:56 AM
Roth Capital Analysts Give Madrigal Pharmaceuticals (MDGL) a $82.00 Price TargetRoth Capital Analysts Give Madrigal Pharmaceuticals (MDGL) a $82.00 Price Target
www.americanbankingnews.com - November 30 at 11:22 AM
Madrigal Pharmaceuticals (MDGL) Earns Buy Rating from Analysts at HC WainwrightMadrigal Pharmaceuticals (MDGL) Earns Buy Rating from Analysts at HC Wainwright
www.americanbankingnews.com - November 29 at 8:12 PM
Benzingas Top Upgrades, Downgrades For November 29, 2017 - BenzingaBenzinga's Top Upgrades, Downgrades For November 29, 2017 - Benzinga
www.benzinga.com - November 29 at 9:52 AM
Breaking Down Madrigal Pharmaceuticals Inc’s (MDGL) Ownership StructureBreaking Down Madrigal Pharmaceuticals Inc’s (MDGL) Ownership Structure
finance.yahoo.com - November 23 at 6:24 AM
Zacks: Brokerages Anticipate Madrigal Pharmaceuticals, Inc. (MDGL) Will Announce Earnings of -$0.65 Per ShareZacks: Brokerages Anticipate Madrigal Pharmaceuticals, Inc. (MDGL) Will Announce Earnings of -$0.65 Per Share
www.americanbankingnews.com - November 21 at 9:24 AM
Madrigal Pharmaceuticals Reports 2017 Third Quarter Financial ResultsMadrigal Pharmaceuticals Reports 2017 Third Quarter Financial Results
finance.yahoo.com - November 12 at 6:01 AM
Madrigal Pharmaceuticals, Inc. (MDGL) Announces  Earnings Results, Beats Estimates By $0.11 EPSMadrigal Pharmaceuticals, Inc. (MDGL) Announces Earnings Results, Beats Estimates By $0.11 EPS
www.americanbankingnews.com - November 10 at 6:44 PM
-$0.84 Earnings Per Share Expected for Madrigal Pharmaceuticals, Inc. (MDGL) This Quarter-$0.84 Earnings Per Share Expected for Madrigal Pharmaceuticals, Inc. (MDGL) This Quarter
www.americanbankingnews.com - October 31 at 9:14 PM
Madrigal Pharmaceuticals Presents Preclinical Results Supporting the Therapeutic Potential of its Lead β-Selective Thyroid Hormone Receptor Agonist, MGL-3196, at AASLD Liver MeetingMadrigal Pharmaceuticals Presents Preclinical Results Supporting the Therapeutic Potential of its Lead β-Selective Thyroid Hormone Receptor Agonist, MGL-3196, at AASLD Liver Meeting
finance.yahoo.com - October 24 at 1:16 AM
Madrigal Pharmaceuticals, Inc. (MDGL) Research Coverage Started at Roth CapitalMadrigal Pharmaceuticals, Inc. (MDGL) Research Coverage Started at Roth Capital
www.americanbankingnews.com - October 19 at 11:44 AM
Madrigal Pharmaceuticals, Inc. (MDGL) PT Raised to $63.00Madrigal Pharmaceuticals, Inc. (MDGL) PT Raised to $63.00
www.americanbankingnews.com - October 13 at 8:22 AM
Analyzing Madrigal Pharmaceuticals (MDGL) and Its PeersAnalyzing Madrigal Pharmaceuticals (MDGL) and Its Peers
www.americanbankingnews.com - September 24 at 10:20 AM
3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher? - Motley Fool3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher? - Motley Fool
www.fool.com - September 24 at 1:10 AM
Madrigal Pharmaceuticals Inc. (MDGL) Has Surged To A New High For The YearMadrigal Pharmaceuticals Inc. (MDGL) Has Surged To A New High For The Year
www.nasdaq.com - September 23 at 8:06 AM
Madrigal Pharmaceuticals, Inc. (MDGL) Research Coverage Started at Evercore ISIMadrigal Pharmaceuticals, Inc. (MDGL) Research Coverage Started at Evercore ISI
www.americanbankingnews.com - September 22 at 7:44 AM
Madrigal Pharma (MDGL) Reports Positive Outcome from Pre-Planned DSMB Safety Review and Completion of ... - StreetInsider.comMadrigal Pharma (MDGL) Reports Positive Outcome from Pre-Planned DSMB Safety Review and Completion of ... - StreetInsider.com
www.streetinsider.com - September 21 at 6:01 PM
Madrigal Pharmaceuticals Announces Positive Outcome from Pre-Planned DSMB Safety Review and Completion of Enrollment of Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial HypercholesterolemiaMadrigal Pharmaceuticals Announces Positive Outcome from Pre-Planned DSMB Safety Review and Completion of Enrollment of Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia
finance.yahoo.com - September 20 at 6:14 AM
Madrigal Pharmaceuticals, Inc. (MDGL) Director Richard S. Levy Acquires 2,000 SharesMadrigal Pharmaceuticals, Inc. (MDGL) Director Richard S. Levy Acquires 2,000 Shares
www.americanbankingnews.com - August 24 at 7:56 PM
Richard S. Levy Acquires 3,550 Shares of Madrigal Pharmaceuticals, Inc. (MDGL) StockRichard S. Levy Acquires 3,550 Shares of Madrigal Pharmaceuticals, Inc. (MDGL) Stock
www.americanbankingnews.com - August 23 at 8:28 PM
Madrigal Pharmaceuticals, Inc. (MDGL) Director Buys $56,374.00 in StockMadrigal Pharmaceuticals, Inc. (MDGL) Director Buys $56,374.00 in Stock
www.americanbankingnews.com - August 22 at 7:56 PM
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Issues  Earnings ResultsMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Issues Earnings Results
www.americanbankingnews.com - August 11 at 12:17 PM
Madrigal reports 2Q lossMadrigal reports 2Q loss
www.cnbc.com - August 11 at 6:24 AM
Madrigal Pharmaceuticals Reports 2017 Second Quarter Financial ResultsMadrigal Pharmaceuticals Reports 2017 Second Quarter Financial Results
finance.yahoo.com - August 11 at 6:24 AM
Madrigal Pharma (MDGL) Completes Enrollment in Phase 2 Proof-of-Concept Study with MGL-3196 for Treatment of NASHMadrigal Pharma (MDGL) Completes Enrollment in Phase 2 Proof-of-Concept Study with MGL-3196 for Treatment of NASH
www.streetinsider.com - August 3 at 4:49 AM
Madrigal Pharmaceuticals Completes Enrollment in Phase 2 Proof-of-Concept Study with MGL-3196 for Treatment of NASHMadrigal Pharmaceuticals Completes Enrollment in Phase 2 Proof-of-Concept Study with MGL-3196 for Treatment of NASH
finance.yahoo.com - August 2 at 5:07 AM
Madrigal Pharmaceuticals Announces $35 Million Private Placement Offering - GlobeNewswire (press release)Madrigal Pharmaceuticals Announces $35 Million Private Placement Offering - GlobeNewswire (press release)
globenewswire.com - June 22 at 8:44 AM

SEC Filings

Madrigal Pharmaceuticals (NASDAQ:MDGL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Madrigal Pharmaceuticals (NASDAQ:MDGL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Madrigal Pharmaceuticals (NASDAQ MDGL) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.